RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 121 filers reported holding RIGEL PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $5,935,000 | +17.3% | 3,243,150 | 0.0% | 0.24% | -9.5% |
| Q1 2020 | $5,059,000 | -27.1% | 3,243,150 | 0.0% | 0.26% | -19.5% |
| Q4 2019 | $6,940,000 | +14.4% | 3,243,150 | 0.0% | 0.33% | -34.7% |
| Q3 2019 | $6,065,000 | -28.4% | 3,243,150 | 0.0% | 0.50% | -15.3% |
| Q2 2019 | $8,465,000 | +1.6% | 3,243,150 | 0.0% | 0.59% | +37.0% |
| Q1 2019 | $8,335,000 | +11.7% | 3,243,150 | 0.0% | 0.43% | +46.3% |
| Q4 2018 | $7,459,000 | -28.4% | 3,243,150 | 0.0% | 0.30% | -34.1% |
| Q3 2018 | $10,411,000 | +13.4% | 3,243,150 | 0.0% | 0.45% | +4.4% |
| Q2 2018 | $9,178,000 | -20.1% | 3,243,150 | 0.0% | 0.43% | -15.9% |
| Q1 2018 | $11,481,000 | -8.8% | 3,243,150 | 0.0% | 0.51% | -1.9% |
| Q4 2017 | $12,583,000 | +52.7% | 3,243,150 | 0.0% | 0.52% | +80.3% |
| Q3 2017 | $8,238,000 | -7.0% | 3,243,150 | 0.0% | 0.29% | -10.2% |
| Q2 2017 | $8,854,000 | -14.7% | 3,243,150 | 0.0% | 0.32% | -10.8% |
| Q1 2017 | $10,375,000 | +34.4% | 3,243,150 | 0.0% | 0.36% | +17.6% |
| Q4 2016 | $7,719,000 | -35.1% | 3,243,150 | 0.0% | 0.31% | -42.5% |
| Q3 2016 | $11,902,000 | +64.6% | 3,243,150 | 0.0% | 0.53% | +42.4% |
| Q2 2016 | $7,232,000 | +7.2% | 3,243,150 | 0.0% | 0.38% | -16.3% |
| Q1 2016 | $6,746,000 | -31.4% | 3,243,150 | 0.0% | 0.45% | -28.4% |
| Q4 2015 | $9,827,000 | +22.7% | 3,243,150 | 0.0% | 0.63% | +18.6% |
| Q3 2015 | $8,011,000 | -23.1% | 3,243,150 | 0.0% | 0.53% | -2.9% |
| Q2 2015 | $10,411,000 | -10.1% | 3,243,150 | 0.0% | 0.54% | +3.8% |
| Q1 2015 | $11,578,000 | +57.3% | 3,243,150 | 0.0% | 0.52% | +46.8% |
| Q4 2014 | $7,362,000 | +17.0% | 3,243,150 | 0.0% | 0.36% | +11.6% |
| Q3 2014 | $6,292,000 | -46.6% | 3,243,150 | 0.0% | 0.32% | -42.0% |
| Q2 2014 | $11,773,000 | -6.4% | 3,243,150 | 0.0% | 0.55% | -10.7% |
| Q1 2014 | $12,583,000 | +36.1% | 3,243,150 | 0.0% | 0.62% | +38.3% |
| Q4 2013 | $9,243,000 | -20.4% | 3,243,150 | 0.0% | 0.45% | -2.8% |
| Q3 2013 | $11,610,000 | +7.2% | 3,243,150 | 0.0% | 0.46% | -5.0% |
| Q2 2013 | $10,832,000 | – | 3,243,150 | – | 0.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CM Management, LLC | 1,500,000 | $1,620,000 | 1.72% |
| Soleus Capital Management, L.P. | 14,803,015 | $15,987,256 | 1.48% |
| ARMISTICE CAPITAL, LLC | 17,136,000 | $18,506,880 | 0.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,228,126 | $1,326,376 | 0.24% |
| GSA CAPITAL PARTNERS LLP | 971,441 | $1,049 | 0.09% |
| NJ State Employees Deferred Compensation Plan | 200,000 | $216,000 | 0.03% |
| Providence Wealth Advisors, LLC | 27,500 | $29,013 | 0.03% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,151,765 | $1,243,906 | 0.03% |
| XTX Topco Ltd | 164,238 | $177,377 | 0.03% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 3,369,076 | $3,638,602 | 0.02% |